Aleksander Ż.
- Country
- Poland
- Department
- Cardiac Intensive Care Unit
Research Overview
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction
- Evaluation of Balcinrenone and Dapagliflozin on Cardiovascular Outcomes in Heart Failure Patients with Renal Impairment: A Phase III Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 961 of 1782 partner sites.
Specializations
Coronary artery disease and acute coronary syndromes
Clinical research activity centers on atherosclerotic cardiovascular disease, myocardial infarction, stable angina, and refractory angina, with attention to event reduction, ischemic risk, and post-acute coronary care.
- Acute coronary syndrome
- Myocardial infarction
- Refractory angina
- Lipoprotein(a)-related risk
Work in this area also includes secondary prevention in patients with established cardiovascular disease and elevated residual risk.
Heart failure and cardiometabolic inflammation
The investigator is actively involved in studies across heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and heart failure with mildly reduced ejection fraction, including forms associated with obesity, systemic inflammation, and impaired functional status.
- HFrEF
- HFpEF
- HFmrEF
- Inflammatory heart failure
This portfolio extends to symptom burden, hospitalization risk, and heart failure progression in complex cardiovascular disease.
Hypertension and kidney disease
Research interests include uncontrolled hypertension, resistant hypertension, and chronic kidney disease, with emphasis on cardiorenal protection and blood pressure control in high-risk patients.
- Resistant hypertension
- Chronic kidney disease
- Proteinuria
- Cardiorenal syndrome
Additional involvement includes prevention of kidney function decline in patients with concomitant cardiovascular disease and heart failure.
Atrial fibrillation and antithrombotic therapy
Clinical trials address atrial fibrillation in the context of coronary disease and intervention, with interest in stroke prevention, bleeding risk, and optimization of antithrombotic treatment after percutaneous coronary intervention.
- Atrial fibrillation
- Dual antithrombotic therapy
- Antiplatelet de-escalation
- Post-PCI management
This area reflects involvement in balancing ischemic protection with bleeding safety in patients with overlapping cardiovascular conditions.
Metabolic and lipid-lowering interventions
The investigator’s research landscape includes obesity, overweight, type 2 diabetes, and novel lipid-focused strategies targeting elevated Lp(a) and broader cardiovascular risk.
- Obesity
- Type 2 diabetes
- Elevated lipoprotein(a)
- Cardiometabolic risk reduction
These activities connect metabolic disease management with prevention of cardiovascular events and progression of organ damage.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.